RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery (RiaCT)

This study has been terminated.
(Insufficient funding to complete total projected enrollment)
CSL Behring
Information provided by (Responsible Party):
Kenichi Tanaka, Emory University
ClinicalTrials.gov Identifier:
First received: January 24, 2011
Last updated: February 2, 2015
Last verified: January 2015

Heart surgery involving valve replacement often involves the use of the heart-lung machine for over 90 minutes, and bleeding tendency is frequently seen. Conventionally, platelet transfusion has been the primary therapy to treat bleeding after this type of procedure. More recently, perioperative supplementation of purified fibrinogen (RiaSTAP, CSL Behring) was shown to reduce bleeding and blood product use (plasma or platelets) after heart surgery. The objective of this trial is to demonstrate the clinical equivalency and economic utility of using fibrinogen concentrate, RiaSTAP for the mitigation of post-operative bleeding in patients in lieu of platelet transfusion.

Purified fibrinogen concentrate has been approved by FDA, and it has been used for the treatment of acute bleeding episodes in patients with low fibrinogen due to hereditary causes (e.g., afibrinogenemia). Compared to the transfusion of platelets which may be associated with volume overload, bacterial/viral infection, immunological effects and excess blood clotting, purified fibrinogen has several advantages. First, it contains no liquid plasma allowing for low volume infusion. Several viral inactivation/reduction steps are used to prepare the fibrinogen concentrate, increasing its viral safety. No antibodies or white blood cells are contained in the fibrinogen concentrate; therefore transfusion reactions are rare. Although platelet transfusion is widely used after heart surgery, there has been no randomized study to endorse this practice. In this study, patients undergoing heart valve replacement will be randomized to receive either platelet (1 unit) transfusion or fibrinogen concentrate (4g) after heparin anticoagulation is reversed. Subjects will be treated only if there is evidence of significant microvascular bleeding. Fifteen minutes after the initial treatment, subjects will be reevaluated for bleeding. If bleeding continues, subjects will be treated with blood transfusion per institutional standard of care.

The primary endpoints for this study are the hemostatic condition of the surgical field and 24-hour total of blood product transfusion.

Condition Intervention Phase
Heart Valve Disease
Coronary Artery Disease
Drug: Human fibrinogen concentrate
Other: apheresis platelets
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: RiaSTAP vs. Conventional Transfusion for Patients Undergoing Valve Replacement Surgery: RiaCT

Resource links provided by NLM:

Further study details as provided by Emory University:

Primary Outcome Measures:
  • Bleeding Scores [ Time Frame: intra-operatively and up to 24 hours postoperatively ] [ Designated as safety issue: No ]
    Bleeding scores are scored on a four-point scale. A visual assessment of surgical field was performed by the senior surgical staff as follows: 0 = excellent hemostasis (dry field), 1 = mild bleeding (oozing), 2 = moderate bleeding (controllable with applied pressure), and 3 = severe bleeding (multiple diffuse bleeding sites). If the visual bleeding scale was 2 to 3, the subjects were randomly assigned to a study intervention using a closed envelope method.

Secondary Outcome Measures:
  • Proportion of Patients in the Fibrinogen Group in Whom Transfusion of Fresh Frozen Plasma or Platelet Concentrate is Required During or After Surgery [ Time Frame: Operative period ] [ Designated as safety issue: No ]
  • Units of Fresh-frozen Plasma (FFP) Transfused-during Surgery and up to 24 Hours After Surgery [ Time Frame: Peri-operative period ] [ Designated as safety issue: No ]
  • Units of Platelets and Allogeneic Red Cells Transfused- During Surgery and up to 24 Hours After Surgery [ Time Frame: Peri-operative period ] [ Designated as safety issue: No ]
  • Blood Loss [ Time Frame: Operative period ] [ Designated as safety issue: No ]

Enrollment: 26
Study Start Date: January 2011
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group A: RiaSTAP
Human fibrinogen concentrate
Drug: Human fibrinogen concentrate
4 g IV once, within 30 minutes of ACT < 155 seconds, post CPB, with evidence of significant microvascular bleeding
Other Name: RiaSTAP
Active Comparator: Group B: apheresis platelets
single apheresis unit
Other: apheresis platelets
A single apheresis platelet unit will be administered as an initial therapy within 30 minutes of ACT <155 seconds post CPB with evidence of significant microvascular bleeding.

Detailed Description:

Platelet and plasma transfusion remain in the mainstay hemostatic therapy for perioperative bleeding. Several studies indicate that acquired fibrinogen deficiency can be the primary cause of bleeding after cardiac surgery. The aim of the study is to compare hematologica and transfusion profiles between the first-line fibrinogen replacement and platelet transfusion in post-cardiac surgical bleeding. In this prospective randomized, open-lable study, 20 adult patients undergoing valve replacement or repair, and fulfilling preset visual bleeding scale (0=excellent hemostasis; 1=oozing; 2=moderate bleeding; 3=severe bleeding from multiple bleeding sites) are randomized to 4 g of fibrinogen or 1 unit of apheresis platelet transfusion. After the initial randomized intervention, additional transfusions are given in the presence of bleeding (>200 ml/hour) according to the institutional practie as follows; 1 apheresis platelet unit if platelet count is less than 100 x 10^9 /L, 2 units of plasma if international normalized ratio is >1.6, or 10 units of cryoprecipitate if fibrinogen level is <200 mg/dL. Primary endpoints include hemostatic condition in the surgical field and 24-hour hemostatic product usage. Hematologica data, clinical outcome, and safety date are collected up to the 28th day postoperative visit.


Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Willing and able to provide written informed consent
  • Age >17 and < 86 years
  • Patients undergoing planned cardiopulmonary bypass (CPB) for:

    1. combined coronary artery bypass grafting and valve replacement/repair surgery
    2. single valve replacement surgery
    3. mitral valve repair surgery

    3. or double valve surgery (aortic and mitral)

  • Presence of clinically relevant microvascular bleeding after protamine administration (hemostasis assessment score of 2-3)
  • Patients should fulfill the following parameters prior to the study intervention:

    • Body temperature > 35.0°C
    • Blood pH > 7.2
    • Hb > 7.0 mg/dL
    • Activated clotting time (ACT) < 155 seconds
    • CPB time > 60 minutes

Exclusion Criteria:

  • Replacement of aorta
  • Planned valve replacement without median sternotomy
  • Previous valve replacement surgery (previous coronary artery bypass graft (CABG) acceptable)
  • History or suspicion of a congenital or acquired coagulation disorder such as hemophilia, von Willebrand disease, and liver disease
  • Hemodialysis dependent renal failure
  • Liver dysfunction (aspartate aminotransferase (AST) or alanine aminotransferase (ALT) increased ≥ 2-fold above the upper limit of local laboratory normal ranges)
  • Known allergy/anaphylaxis to fibrinogen concentrate or apheresis platelet units
  • Clopidogrel administration within 5 days of surgery
  • Coumadin (warfarin) administration within 5 days of surgery
  • Participation in another clinical study in the 4 weeks preceding surgery
  • Any indication that a potential subject did not comprehend the study restrictions, procedures, or consequences therein an informed consent cannot be convincingly given
  • Life expectancy less than 48 hours
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01283321

United States, Georgia
Emory University Hospital
Atlanta, Georgia, United States, 30322
Sponsors and Collaborators
Emory University
CSL Behring
Principal Investigator: Gautam Sreeram, MD Emory University
Principal Investigator: Kenichi Tanaka, MD, MSc University of Maryland
  More Information

No publications provided by Emory University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Kenichi Tanaka, MD, Emory University
ClinicalTrials.gov Identifier: NCT01283321     History of Changes
Other Study ID Numbers: IRB00036062, RiaCT 2010
Study First Received: January 24, 2011
Results First Received: January 20, 2015
Last Updated: February 2, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Emory University:
Cardiopulmonary bypass (heart-lung machine)

Additional relevant MeSH terms:
Coronary Artery Disease
Coronary Disease
Heart Valve Diseases
Myocardial Ischemia
Arterial Occlusive Diseases
Cardiovascular Diseases
Heart Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on October 09, 2015